Dow Jones Newswires: Enhertu significantly delayed breast cancer progression in trial, AstraZeneca says


AstraZeneca PLC said Monday that its Enhertu drug significantly delayed metastatic breast cancer progression in a Phase 3 trial, reinforcing the results of a prior trial.

The Anglo-Swedish pharma giant AZN, +1.98% said results from the Destiny-Breast02 Phase 3 trial of Enhertu–trastuzumab deruxtecan–showed the trial met the primary endpoint, demonstrating a significant and clinically meaningful improvement in progression-free survival in patients.

Enhertu is being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo Ltd.

Write to Kyle Morris at

This article was originally published by Read the original article here.

Previous articleDow Jones Newswires: China new-home prices fall by most in over six years
Next articleIran denies involvement in Salman Rushdie attack


Please enter your comment!
Please enter your name here